364 related articles for article (PubMed ID: 31601253)
21. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
Kim CY; Kim YC; Oh JH; Kim MH
Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
[TBL] [Abstract][Full Text] [Related]
22. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
[TBL] [Abstract][Full Text] [Related]
23. Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer.
Guney Eskiler G; Cecener G; Dikmen G; Egeli U; Tunca B
Eur J Pharm Sci; 2018 Jul; 120():73-88. PubMed ID: 29719240
[TBL] [Abstract][Full Text] [Related]
24. Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells.
You D; Jung SP; Jeong Y; Bae SY; Lee JE; Kim S
BMB Rep; 2017 Dec; 50(12):615-620. PubMed ID: 28855026
[TBL] [Abstract][Full Text] [Related]
25. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
[TBL] [Abstract][Full Text] [Related]
27. Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β-catenin signalling to restore tamoxifen sensitivity.
Li P; Feng C; Chen H; Jiang Y; Cao F; Liu J; Liu P
J Cell Mol Med; 2018 Jul; 22(7):3423-3433. PubMed ID: 29602199
[TBL] [Abstract][Full Text] [Related]
28. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
[TBL] [Abstract][Full Text] [Related]
29. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
30. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
31. CCAT2 knockdown inhibits cell growth, and migration and promotes apoptosis through regulating the hsa-mir-145-5p/AKT3/mTOR axis in tamoxifen-resistant MCF7 cells.
Moradi F; Mohajerani F; Sadeghizadeh M
Life Sci; 2022 Dec; 311(Pt B):121183. PubMed ID: 36375570
[TBL] [Abstract][Full Text] [Related]
32. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells.
Liang Z; Li W; Liu J; Li J; He F; Jiang Y; Yang L; Li P; Wang B; Wang Y; Ren Y; Yang J; Luo Z; Vaziri C; Liu P
Sci Rep; 2017 Feb; 7():41776. PubMed ID: 28150753
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
[TBL] [Abstract][Full Text] [Related]
34. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
36. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
38. Non-canonical AR activity facilitates endocrine resistance in breast cancer.
Chia K; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E
Endocr Relat Cancer; 2019 Feb; 26(2):251-264. PubMed ID: 30557851
[TBL] [Abstract][Full Text] [Related]
39. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.
Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J
Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959
[TBL] [Abstract][Full Text] [Related]
40. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]